Preclinical Studies

Good Laboratory Practice (GLP) [21 CFR Part 58]

Good Laboratory Practice (GLP) deals with the organization, process and conditions under which laboratory studies are planned, performed, monitored, recorded and reported. These practices are intended to promote the quality and validity of Preclinical test data. Preclinical safety and toxicology studies should be performed under GLP conditions if they are intended to support applications for research or marketing permits to the FDA.

A properly designed and documented GLP study should make it possible to answer the following questions both during the study for the researchers, and also after the study for FDA auditing, and also 10 years or more later:

  • Who performed the study?
  • How was the experiment carried out?
  • Which procedures were used?
  • Were there any problems?
  • How were problems solved?

A list of frequently asked questions is available at the FDA web page for GLP Guidance for Industry. This provides answers to some of the basic queries surrounding GLP Preclinical studies.

Please provide notification 4-6 months in advance of a planned start date for any GLP studies.

 

Click here to email the Research Help Desk                    Click here to Request a Consultation

 

NIH Funding Acknowledgement ** Important ** All publications resulting from the utilization of CTSI resources are required to credit the CTSI grant by including the NIH FUNDING ACKNOWLEDGEMENT and must comply with the NIH Public Access Policy.